Progenics Pharmaceuticals Sets Fourth Quarter and Full-Year 2018 Financial Results and Business Update Call for March 14
07 mars 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
Progenics Acquires AZEDRA® (iobenguane I 131) Radiopharmaceutical Manufacturing Facility
11 févr. 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™
03 janv. 2019 01h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
Progenics Pharmaceuticals Expands Leadership Team with Appointment of Asha Das, M.D. as Chief Medical Officer
02 janv. 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
Progenics Doses First Patient in Pivotal Phase 3 Study of PyL, PSMA PET Imaging Agent, for the Detection of Prostate Cancer
03 déc. 2018 08h30 HE
|
Progenics Pharmaceuticals Inc.
-Potential to Improve Early Detection and Transform the Treatment Landscape for Recurrent Prostate Cancer - NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc....
Progenics Pharmaceuticals Announces Presentation of Updated Safety and Tolerability Data for AZEDRA® (iobenguane I 131) at the Radiological Society of North America (RSNA) Annual Meeting
19 nov. 2018 16h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
Progenics Pharmaceuticals Announces Third Quarter 2018 Financial Results And Business Update
08 nov. 2018 07h30 HE
|
Progenics Pharmaceuticals Inc.
AZEDRA® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA)AZEDRA U.S. Launch Progressing and AZEDRA Added to the NCCN Guidelines and Four CMS-Recognized Drug CompendiaPhase 3 Study...
Progenics Pharmaceuticals to Present at Upcoming Investor Conferences
06 nov. 2018 08h00 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
Progenics Pharmaceuticals Sets Third Quarter 2018 Financial Results and Business Update Call for November 8
01 nov. 2018 08h00 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
Progenics Advances 1095, PSMA-Targeted Therapeutic Candidate for the Treatment of Metastatic Prostate Cancer, into Phase 2 Clinical Development Following Discussions with the FDA
11 oct. 2018 16h01 HE
|
Progenics Pharmaceuticals Inc.
– Trial will utilize PyL imaging in order to target the patients most likely to benefit, advancing the Company’s theranostic approach to the treatment of prostate cancer – NEW YORK, Oct. 11, 2018 ...